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ing of the molecular events and signal transduction path-
ways responsible for the development of IH has yet to be
established.
A novel nonreceptor tyrosine kinase known as the
focal adhesion kinase (FAK) is a critical mediator of sig-
naling events between cells and their extracellular matrix.
This 125-kD protein (p125FAK) is ubiquitously expressed
in most tissues and is localized to discrete regions along
ventral cell surfaces known as focal adhesions where inte-
grin receptors interact with extracellular matrix proteins of
the underlying substratum.2-4 FAK is the major tyrosine-
phosphorylated protein in focal adhesions and has been
shown to interact with integrins,5 other tyrosine kinases
(Src, Fyn),6 and growth factors (VEGF, PDGF).7,8 FAK
has been linked to cancer and appears to be involved in the
proliferative changes when human tumors progress from
benign to invasive phenotypes.9-12 In tumor cells, FAK is
thought to have a dual function, both promoting tumor
cell adhesion and acting as a survival signal to inhibit
apoptosis as a tumor develops anchorage-independent
growth properties.13 Thus, in both healthy and neoplastic
cells, FAK appears to be a key element in signal transduc-
tion pathways used in cell adhesion,14 motility,15 and
apoptosis.16-18 Because similar alterations in these cellular
processes occur in VSMCs during IH,19,20 we studied
The long-term success of bypass grafting and angio-
plasty for the treatment of atherosclerotic occlusive disease
is limited by the development of intimal hyperplasia (IH),
the most common cause of reconstructive failure.1 IH is a
complex process occurring in the vessel wall after endothe-
lial cell injury. Vascular smooth muscle cell (VSMC)
migration and proliferation and extracellular matrix depo-
sition leads to intimal thickening, luminal narrowing, and
eventual vessel thrombosis. Efforts to better understand
the molecular genetics involved in IH have included many
studies that examine the role of inflammatory cells,
growth factors, extracellular matrix proteins, and nitric
oxide. Nevertheless, despite advances, a clear understand-
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Purpose: The migration and proliferation of vascular smooth muscle cells (VSMCs) are important events in the devel-
opment of intimal hyperplasia (IH). The focal adhesion kinase (FAK) gene encodes a protein tyrosine kinase (p125FAK)
involved in signal transduction pathways used in cell adhesion, motility, and proliferation. Because alterations in these
cellular processes are thought to occur in VSMCs during IH, we studied FAK expression in healthy arteries and veins
in comparison with that in pathologic vessels containing IH.
Methods: To determine p125FAK expression at the cellular level, we developed a monoclonal antibody that specifically
detected FAK in formalin-fixed, paraffin-embedded tissue sections (5 µm) and analyzed the levels of FAK expression in
human arteries and veins. Specificity of monoclonal antibody 4.47 was demonstrated by means of immunofluorescence
microscopy showing FAK-specific staining at focal adhesions of healthy human vascular smooth muscle cells (AoSMCs).
By using immunohistochemistry techniques, we analyzed the expression of p125FAK in 25 adult human vascular tissue
samples from individual patients, which contained a histologically confirmed healthy artery, vein, or IH.
Results: FAK expression in healthy and pathologic human vascular tissue was localized predominantly within VSMC
cytoplasm. In healthy human artery and vein, borderline FAK expression was detected in the media of seven of 17 
vessels and undetectable in the remainder of specimens. However, in vessels containing IH, FAK was overexpressed 
in the pathologic VSMC populations at moderate-to-strong levels in eight of eight specimens. The levels of FAK expres-
sion were directly correlated with structures containing IH, and the results of FAK staining intensity and the percent-
age of positive cells in these samples were significantly increased compared with normal vascular tissue levels (P < .05,
Student t test).
Conclusion: These results provide the first evidence that FAK is overexpressed in VSMCs involved in IH and suggest
that FAK upregulation may be part of a mechanism for migration and proliferation of VSMCs during this process.
Furthermore, the dramatic upregulation of FAK in IH and the relative lack of expression in healthy vessels suggest that
FAK may be a rational target for controlling IH. (J Vasc Surg 2001;34:344-9.)
FAK expression in a variety of healthy and abnormal
human vascular tissues.
METHODS
Primary tissues and cell lines. Twenty-five adult
human vascular tissue samples were obtained from opera-
tive specimens banked through protocols approved by the
Institutional Review Board at the University of North
Carolina (UNC) Hospitals. Histopathologic tissue confir-
mation was performed on all specimens by a reference
pathologist (M.V.I.), and hematoxylin and eosin-stained
sections were reviewed, with areas of healthy artery, vein,
and IH identified. The samples containing IH were from
preocclusive vein graft stenoses obtained at the time of pri-
mary graft revision. The vascular tissues were sharply dis-
sected from adjacent tissues, and samples were
formalin-fixed, paraffin-embedded (FFPE) and stored by
the UNC-Lineberger Comprehensive Cancer Center
Tissue Procurement and Analysis Facility. Human cell lines
were obtained from Clonetics (San Diego, Calif).
Immunofluorescence microscopy. Human aortic
endothelial cells (HAECs) and human aortic smooth mus-
cle cells (AoSMCs; 5 × 104) were plated onto cover slips
in 6-well tissue culture dishes and fixed in 3.7% formalde-
hyde. After permeabilization in 0.1% Triton X-100, the
cells were blocked with 10% normal goat serum and incu-
bated with anti-FAK (4.47) monoclonal antibody (1:50
dilution), an antibody that our group had developed ear-
lier (available from Upstate Biotechnology, Lake Placid,
NY).21 After incubation with the secondary antibody con-
jugated with fluoresceine isothiocyanate (Molecular
Probes, Eugene, Ore), positive cells were visualized and
photographed with a Zeiss fluorescence microscope. The
cells were co-stained with antipaxillin monoclonal anti-
body (Transduction Laboratory, Lexington, Ky) with
rhodomamine conjugated secondary antibody to deter-
mine the specific localization of p125FAK. Paxillin is a focal
adhesion protein.
Immunohistochemistry assays. Five-micron thick
vascular tissue sections were cut from corresponding FFPE
blocks and subsequently deparaffinized and hydrated by
passing through xylene and a graded series of ethanol con-
centrations (100%-70%). Endogenous peroxidase activity
was quenched with 3% hydrogen peroxide, and mercuric
pigments were removed by incubating sections in
Auto/Iodine (Fischer Scientific) for 1 minute. Slides were
incubated in Redusol (Fischer Scientific), a nonspecific
blocking agent, two times for 2 minutes. The hydration
process was completed by rinsing three times for 3 min-
utes in 1× Automation Buffer (Fischer Scientific).
Heat-induced epitope recovery was used by submerg-
ing the sections in 1× Antigen Retrieval Citra Buffer
(Biogenex) and steam heating in a standard steamer (Black
and Decker) for 30 minutes. After blocking in normal
horse serum for 15 minutes, the sections were incubated
with anti-FAK 4.47 monoclonal antibody (1:50 dilution,
0.3 µg) overnight at 4°C. Control sections were incubated
with a comparable concentration (1:37, 0.3 µg) of iso-
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type-matched IgG1 monoclonal antibody, MOPC-21
(Sigma, St Louis, Mo), and a VSMC marker and α-actin
monoclonal antibody (1:100, 0.15 µg; Sigma). After
extensive washings in automation buffer, the sections were
incubated with biotinylated horse anti-mouse IgG, fol-
lowed by avidin peroxidase with the Vectastatin ABC elite
kit (Vector Laboratories, Burlingame, Calif). The chro-
mogenic reaction was performed with 3-3’ diaminobenzi-
dine (DAB), toned with the DAB enhancing solution
Fig 1. Immunofluorescence microscopy of p125FAK expression
in human vascular endothelial and smooth muscle cells. Indirect
immunofluorescence demonstrates focal adhesion kinase staining
at focal adhesions. A, Human aortic endothelial cells. B, Human
aortic smooth muscle cells. C, Dual immunofluorescence staining
demonstrates that focal adhesion kinase (red) and paxillin (green)
co-localize at focal adhesions (yellow) in human aortic smooth
muscle cells.
(Vector Laboratories). The sections were counterstained
with hematoxylin, washed in 1× automation buffer, and
dehydrated in 100% ethanol and xylene.
Immunohistochemistry scoring. Each tissue section
was scored for FAK expression by a single pathologist
blinded to the source. Smooth muscle cells from each sec-
tion were scored for staining intensity on the basis of this
scoring system: 0, none; 1+, borderline; 2+, weak; 3+,
moderate; 4+, strong. Staining characteristics of cellular
localization (cytoplasm, nucleus, membrane, or a combi-
nation thereof) and overall distribution (homogeneous
throughout cell population, unifocal, heterogeneous, or
multifocal) were recorded.
Statistics. The statistical differences between staining
intensity and the percentage of positive cells in healthy vas-
cular tissue and IH were evaluated by means of the
Student t test at an overall .05 level. Values are expressed
as the mean ± SE.
RESULTS
Immunofluorescence microscopy of p125FAK
expression in human vascular endothelial and smooth
muscle cells. Indirect immunofluorescence microscopy
was performed on HAECs and AoSMCs to determine the
presence of p125FAK expression at the cellular level in cells
isolated from healthy human vascular tissue. Our anti-FAK
monoclonal antibody (4.47) localized p125FAK specifically
to the focal adhesions of these cells (Fig 1). Furthermore,
dual-staining of FAK and paxillin, a focal adhesion protein
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known to associate with FAK,14 demonstrated that these
two proteins colocalized at focal adhesion sites.
Overexpression of p125FAK in intimal hyperplasia.
To characterize FAK expression in vascular disease, we
extended our studies to human tissues performing
immunohistochemistry (Table). In all specimens demon-
strating FAK expression (healthy and IH), FAK was local-
ized predominately within the cytoplasm of VSMCs, and
the levels of p125FAK expression were heterogeneous in
pathologic specimens containing smooth muscle cell pop-
ulations involved in IH. The presence of VSMCs con-
tained within the IH of the samples studied was confirmed
on adjacent sections after immunohistochemical staining
for α-actin, a VSMC marker.
In the 17 samples of healthy vascular tissue obtained
from patients encompassing healthy veins and arteries,
there was little detectable p125FAK expression within the
VSMCs (Fig 2). Only five samples of venous tissue (from
patients 1, 4, 5, 9, and 10) demonstrated any FAK
immunoreactivity, with only minimal (1+) expression in
5% of the VSMCs comprising the media of these samples.
Likewise, FAK levels in the smooth muscle cells contained
within the media of healthy human artery was low, with
only two samples (patients 13 and 15) showing any
detectable expression (1+) in 5% of the cells.
In contrast, p125FAK was detected at high levels in all
eight of the IH specimens we tested. The significant
upregulation of FAK expression in these IH specimens is
demonstrated in the near-occlusive venous bypass graft
Immunohistochemical analyses of p125FAK expression in healthy artery, vein, and intimal hyperplasia
Patient Tissue type* Staining intensity % positive cells
1 Vein + 5
2 Vein 0 0
3 Vein 0 0
4 Vein + 5
5 Vein + 5
6 Vein 0 0
7 Vein 0 0
8 Vein 0 0
9 Vein + <5
10 Vein + <5
11 Vein 0 0
12 Vein 0 0
13 Artery + 5
14 Artery 0 0
15 Artery + 5
16 Artery 0 0
17 Artery 0 0
18 IH +++ 30
19 IH +++ 60
20 IH +++ 80
21 IH ++++ 90
22 IH ++++ 80
23 IH +++ 40
24 IH +++ 40
25 IH ++++ 60
*Histologically confirmed tissue. 
Vein, Healthy vein media, vascular smooth muscle cells; Artery, healthy artery media, vascular smooth muscle cells; IH, intimal hyperplasia, vascular smooth
muscle cells.
lesion from patient 21 (Fig 3). This sample contained a
failing infrainguinal autogenous vein bypass graft. Here,
the occlusive process of IH containing the pathologic
VSMCs demonstrated strong (4+) FAK expression
throughout the cytoplasm of most (95%) of the VSMCs.
The intensity of FAK expression in IH VSMCs ranged
from moderate (3+) to strong (4+) in the smooth muscle
cells (mean = 3.4 ± 0.5) from the pathologic populations
involved in IH. Smooth muscle cells from adjacent histo-
logically normal areas demonstrated minimal FAK expres-
sion. However, the entire population of VSMCs was not
involved in the intimal hyperplastic specimens overex-
pressed p125FAK. As noted in the Table, there was a vari-
ability in the percentage of VSMCs demonstrating positive
FAK staining, ranging from 30% to 90% (mean, 60 ± 22)
of smooth muscle cells (Fig 4). The results from staining
intensity and the percentage of positive cells in IH were
significantly different from the expression levels found in
healthy tissue (P < .05, Student t test). Because the vascu-
lar tissue specimens studied were from isolated early
(healthy tissue) and late stages (near-occlusive lesions) of
the intimal hyperplastic process, a conclusion about the
timing of FAK expression in the vessel wall during this
process remains unclear.
DISCUSSION
These results provide the first evidence that the capac-
ity of VSMCs to undergo IH is accompanied by the over-
expression of p125FAK. From our data, we conclude that
VSMCs contained within healthy arteries and veins are not
accompanied by aberrant p125FAK expression. In contrast,
significantly high levels of FAK expression were present in
VSMCs contained within primary near-occlusive lesions
obtained from failing bypass grafts. The smooth muscle
cells in these intimal lesions had migrated from the media
across the external elastic lamina into the intima, creating
a hyperplastic process. Taken together, these results sug-
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gest that the FAK may be a part of a signaling pathway in
VSMCs that promotes IH.
It is intriguing to speculate why p125FAK might
become overexpressed in VSMCs as part of the intimal
hyperplastic process. FAK is a normal gene with detectable
levels in all tissues including blood vessels2,22 and no evi-
dence for mutations, which would render it a transform-
ing gene.23 In healthy cells, FAK is a critical mediator of
signaling events between cells and their extracellular
matrix while being linked to cell adhesion,14 motility,15
and apoptosis.16-18,24 The ongoing events observed in the
early development of IH appear to be explained by specific
hemodynamic factors and inflammatory cell pathways.1
However, although the mechanisms are not well under-
stood, the migration and proliferation of VSMCs may be
later events in IH that require additional molecular
changes.25 Smooth muscle cells may develop further sig-
naling imbalances that lead to alterations in cell adhesion
and motility, allowing VSMCs to migrate through the
external elastic lamina and potentially develop IH.
A phenomenon similar to this has been shown to
occur in cancer. High levels of FAK expression were
observed in human invasive and metastatic tumors as
tumor cells became invasive and migrated through the
extracellular matrix.4-7 Furthermore, FAK has been shown
to be a survival signal for cells that grow independent of
matrix signaling, and the downregulation of FAK function
in tumor cells, which grow in an anchorage-independent
manner, has been shown to result in apoptosis.13 Thus, if
similar events occur during the process of IH, it is con-
ceivable that VSMCs upregulate FAK expression to
acquire the ability to migrate, proliferate, and survive
within the intimal area of an injured vessel.
Finally, our observations raise the possibility that FAK
might be a rational therapeutic target to interrupt the inti-
mal hyperplastic process. Because we have reproducibly
demonstrated minimally detectable p125FAK levels in
Fig 2. Expression of p125FAK in healthy human artery and vein (400×). No detectable FAK expression is observed in vascular smooth mus-
cle cells comprising media of healthy human artery (A) and vein (B).
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Fig 3. p125FAK overexpression in intimal hyperplasia. Cross section of segment of infrainguinal autogenous vein bypass graft contain-
ing intimal hyperplasia. Near-occlusive tissue contains migrating vascular smooth muscle cells and extracellular matrix material involved
in proliferation of intimal hyperplasia. Arrow marks the edge of the vessel wall. A, Cross section of venous bypass graft demonstrating
intense, diffuse immunoreactivity for p125FAK (200×). B, Higher magnification demonstrating p125FAK overexpression in vascular
smooth muscle cells (400×). C, Highest magnification demonstrating p125FAK overexpression contained within cytoplasm of vascular
smooth muscle cells (600×). D, Cross section of venous bypass graft demonstrating diffuse immunoreactivity for α-actin (400×). 
E, Cross section of venous bypass graft after immunohistochemical staining for isotype-matched IgG1 (400×). IH, Intimal hyperplasia.
Fig 4. Graphical representation of p125FAK expression levels in healthy vein and artery, compared with vessels containing intimal hyperpla-
sia. Staining intensity (0 to 4+) is represented on y-axis. Also indicted is focal adhesion kinase expression distribution (% positive staining).
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healthy vascular tissue and high levels of p125FAK in IH, it
would be useful to study the effects of attenuating FAK
expression in VSMCs involved in IH. If this causes dis-
ruption of the intimal hyperplastic process, molecular-
based therapeutics against FAK may become useful in the
treatment of IH.
We thank Lynn Dressler and the Tissue Procurement
and Analysis Core Facility of the UNC Lineberger
Comprehensive Cancer Center for immunohistochemistry
advice and tissue specimens.
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